YH44529 / Cyrus Therap, Kanaph Therap, Yuhan Corp - LARVOL DELTA

Cyrus announces research results on anticancer drugs targeting GSPT1, SOS1, and CDK7 at the U.S. AACR [Google translation] (HIT News) - "Cyrus...announced on the 8th...that it had made three presentations at the American Association for Cancer Research...Through this announcement, the company revealed the results showing that CYRS1542 was effective in treating neuroendocrine tumors (small cell lung cancer, neuroendocrine prostate cancer, etc.) that have a very poor clinical prognosis and lack appropriate treatment options. They also disclosed various cell and animal test results showing that it has a wider therapeutic index compared to competing clinical-stage substances...the drug efficacy evaluation results of various rodent models transplanted with KRAS or EGFR mutant non-small cell carcinoma (NSCLC) or pancreatic cancer (PDAC) cells showed that CK-1001 combination therapy kills cancer cells better than existing treatments....C-16661 had high selectivity for CDK7 and properties suitable for oral administration, and strongly inhibited the growth of various cancer cells."

Preclinical • Lung Cancer • Neuroendocrine Tumor • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Prostate Cancer • Small Cell Lung Cancer • Solid Tumor

Yuhan Signs $166mn Global Deal for SOS1 Inhibitor with Cyrus and Kanaph [Google translation] (HIT News) - "Yuhan Pharmaceuticals...has officially entered into a global licensing agreement with Cyrus Therapeutics and Kanaph Therapeutics for the development and commercialization of an anti-cancer agent targeting SOS1. The exclusive global implementation rights were disclosed in a public announcement on March 7th...The contract outlines the exclusive global rights for the development and commercialization of a compound inhibiting the activity of the SOS1 protein...The contract, valued at up to $166 million, includes an initial payment of $4.8 million, with milestone payments based on development, approval, and sales, capped at a maximum of $162 million....'By securing additional reinforcements to our anticancer drug pipeline through this contract, we have taken a significant step forward in the development of our second and third generations of Leclaza.'"

Licensing / partnership • Oncology